Incyte Corporation

NASDAQ:INCY

Biotechnology

Healthcare
$117.80 -0.78%

-$0.77 today

Market cap
$24.01B
Beta
0.79
P/E (TTM)
13.7
EPS (TTM)
$7.18
52W Low $66.74High $112.29

Volume 1.21M

Average 1.58M

INCY Gross Margin

Gross profit as a percentage of revenue, showing how much of each sales dollar is kept after direct costs.

Incyte CorporationNASDAQ: INCY

Gross Margin · Q2 FY2026 · quarter ended Jun 2026

Gross margin holds steady near 93.7%

Gross margin was 93.7% in Q2 FY2026, up 0.2 pp from a year earlier. On a trailing-twelve-month basis it was 92.6%, down 0.3 pp year over year. Over 3 fiscal years it narrowed by 1.1 pp.

Context

  • Gross margin widened in 1 of the last 3 fiscal years.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterJun 2026
93.7%+1.9 pp QoQ
Last fiscal yearDec 2025
92.8%+0.1 pp YoY
LTMJun 2026
92.6%-0.3 pp YoY
Gross Margin past and forecast change by horizon
Horizon Past Forecast Difference
Quarter+0.2 pp——
1 year+0.1 pp——
3 years-1.1 pp——
5 years——
10 years——

Gross Margin history

Percent of revenue · from the income statement

Latest · FY2025
92.8%
Year-over-year change
+0.1pp

Gross Margin vs competitors

How INCY compares with its peers on the latest reported figures

  • INCY's LTM Jun 2026 gross margin of 92.6% is the 4th highest of the 8 companies compared; the peer median is 86.5%.
  • Its year-over-year change of -0.3 pp is the 4th highest of 7, against a peer median of -0.4 pp.
  • Over three fiscal years its change of -1.1 pp compares with a peer median of -0.0 pp.
INCY Competitors Peer median
Gross Margin for INCY and competitors
Company Period LTM level YoY 3-year change
LGNDLigand Pharmaceuticals IncorporatedLTM Jun 202698.6% +10.9 pp+24.5 pp
EXELExelixis, Inc.LTM Jul 202696.5% -0.1 pp-0.0 pp
GMABGenmab A/SLTM Jun 202693.0% —-8.3 pp
INCYIncyte CorporationLTM Jun 202692.6% -0.3 pp-1.1 pp
NRIXNurix Therapeutics, Inc.LTM Aug 202686.5% +249.4 pp+455.2 pp
REGNRegeneron Pharmaceuticals, Inc.LTM Jun 202684.9% -0.7 pp-0.6 pp
VSTMVerastem, Inc.LTM Mar 202683.7% -16.3 pp-17.1 pp
LEGNLegend Biotech CorporationLTM Sep 202657.0% -3.6 pp+16.2 pp
SLSSELLAS Life Sciences Group, Inc.FY2025— ——
AVBPArriVent BioPharma, Inc. Common StockFY2025— ——
CGEMCullinan Therapeutics, Inc.FY2025— ——
Peer median (excluding INCY) 86.5%-0.4 pp-0.0 pp

Competitors are the stored peer set for INCY. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue2.99B3.39B3.7B4.24B5.14B
Cost of Revenue150.99M207M254.99M312.1M372.1M
Gross Profit2.84B3.19B3.44B3.93B4.77B
Gross Margin94.9%93.9%93.1%92.6%92.8%
Research & Development1.46B1.59B1.63B2.61B2.05B
Selling, General & Admin739.56M1B1.16B1.22B1.38B
Operating Expenses2.25B2.6B2.79B3.83B3.43B
Depreciation & Amortization57.84M67.86M82.66M89.25M93.29M
EBITDA630.2M599.64M919.43M408.16M1.76B
EBITDA Margin21.1%17.7%24.9%9.6%34.2%
Operating Income585.78M591.63M655.36M101.29M1.34B
Operating Margin19.6%17.4%17.7%2.4%26.1%
Interest Income000128.71M105.6M
Interest Expense1.91M2.67M2.55M2.28M2.43M
Other Income / Expenses(15.33M)(62.51M)178.86M215.34M321.66M
Income Before Tax570.44M529.12M834.22M316.63M1.66B
Pre-Tax Margin19.1%15.6%22.6%7.5%32.4%
Income Tax Expense(378.14M)188.46M236.62M284.02M377.8M
Net Income948.58M340.66M597.6M32.62M1.29B
Net Margin31.8%10.0%16.2%0.8%25.0%
EPS (Basic)4.301.532.670.166.59
EPS (Diluted)4.271.522.650.156.41
Weighted Avg Shares220.43M222M223.63M207.11M195.2M
Weighted Avg Shares (Diluted)222.07M223.96M225.93M210.53M200.7M

Incyte Corporation

NASDAQ:INCY

Intrinsic Alpha fair value

Locked

Current Price

$117.80

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.